>>Plant in Porri ño Spain was successfully producing Avastin.
>>Ebersman think other cancer patients might benefit from Avastin.
>>Genentech tested Avastin on other forms of cancer.
If Avastin can approved by FDA
>>Genentech may need to expand its capacity to meet demand.
At least we need 5 years for completed the Genentech’s clinical trials.
But don’t know >> how many cancer patients could benefit.
>> how alternative cancer drugs from other companies will get this clinical trials.
Slide 2005 Most Admired Biotech Company
In 1976 , Genentech was founded by Venture Capitalist (Robert A. Swanson & Dr. Herbert W. Boyer)
In 1977, Licensed first recombinant DNA drug to Eli Lilly
In 1980 , Product Public in USA.
In 1990 , Roche Holding Ltd. Invested $2.1billon
in Nov.2004 , Value of firm $52 billion (Roche held 60 % of common stock)
Oncology Product / Pipeline focus
1AVASTIN : drug for patients with previously untreated metastatic cancer of the colon or rectum Slide Overview Mission To be the leading biotechnology company, using human genetic information to discover, develop, manufacture and commercialize biotherapeutics that address significant unmet medical needs. In 2003 Revenues : $3,300 million 79 % from product sales Net Income: $563 million In 2004 AVASTIN 1 was approved by FDA First nine months of 2004 sales of AVASTIN 15 % or $2,684,000 million TARCEVA & OMNITARG both drugs that Genentech promise to launch in the next year
Genentech Product Information (2001-2003) Slide ($ in millions)
Six primary groups:
Legal and human resources
Slide In 2004 Product Operation Product development Part in
Senior Vice President Product Operation
Experienced for 10 years
Responsible for manufacturing , process development , supply chain management , engineering and operational (these staff 2,500 people)
South San Francisco (SSF)
Slide To created drugs based on recombinant DNA (inserting DNA into cells to produce protein) Operation Locations Vacaville (CA ) Porri ño Spain